中国肿瘤临床
中國腫瘤臨床
중국종류림상
CHINESE JOURNAL OF CLINICAL ONCOLOGY
2014年
24期
1556-1560
,共5页
软组织肉瘤%手术%化疗%放疗%靶向治疗
軟組織肉瘤%手術%化療%放療%靶嚮治療
연조직육류%수술%화료%방료%파향치료
soft tissue sarcoma%surgery%chemotherapy%radiotherapy%targeted therapy
肉瘤是一组少见的具有不同临床和病理特征的间叶来源的肿瘤。整体上肉瘤可分为两大类,软组织来源的肉瘤和骨肉瘤。肉瘤大约占成人恶性肿瘤的1%,占儿童恶性肿瘤的15%。软组织肉瘤包含50多种不同的组织学亚型,最常见的亚型包括未分化多形性肉瘤、胃肠间质瘤、脂肪肉瘤、平滑肌肉瘤、滑膜肉瘤和恶性外周神经鞘瘤等。手术是软组织肉瘤最主要的治疗方法,但术后复发率高,预后差,化疗疗效仍不理想。随着人们对其生物学行为认识的加深,近些年涌现的一系列新型靶向药物取得了不错的疗效。总之,软组织肉瘤的治疗需根据疾病的组织学亚型、分子遗传学特点、分期及预后因素采取包括手术、放疗、化疗以及分子靶向治疗在内的个体化治疗模式。
肉瘤是一組少見的具有不同臨床和病理特徵的間葉來源的腫瘤。整體上肉瘤可分為兩大類,軟組織來源的肉瘤和骨肉瘤。肉瘤大約佔成人噁性腫瘤的1%,佔兒童噁性腫瘤的15%。軟組織肉瘤包含50多種不同的組織學亞型,最常見的亞型包括未分化多形性肉瘤、胃腸間質瘤、脂肪肉瘤、平滑肌肉瘤、滑膜肉瘤和噁性外週神經鞘瘤等。手術是軟組織肉瘤最主要的治療方法,但術後複髮率高,預後差,化療療效仍不理想。隨著人們對其生物學行為認識的加深,近些年湧現的一繫列新型靶嚮藥物取得瞭不錯的療效。總之,軟組織肉瘤的治療需根據疾病的組織學亞型、分子遺傳學特點、分期及預後因素採取包括手術、放療、化療以及分子靶嚮治療在內的箇體化治療模式。
육류시일조소견적구유불동림상화병리특정적간협래원적종류。정체상육류가분위량대류,연조직래원적육류화골육류。육류대약점성인악성종류적1%,점인동악성종류적15%。연조직육류포함50다충불동적조직학아형,최상견적아형포괄미분화다형성육류、위장간질류、지방육류、평활기육류、활막육류화악성외주신경초류등。수술시연조직육류최주요적치료방법,단술후복발솔고,예후차,화료료효잉불이상。수착인문대기생물학행위인식적가심,근사년용현적일계렬신형파향약물취득료불착적료효。총지,연조직육류적치료수근거질병적조직학아형、분자유전학특점、분기급예후인소채취포괄수술、방료、화료이급분자파향치료재내적개체화치료모식。
Sarcomas consist of a group of rare solid tumors of mesenchymal cell origin with distinct clinical and pathological fea-tures. Generally, they are divided into two categories: sarcoma of soft tissue and sarcoma of bone. Sarcomas account for approximately 1% of all adult malignancies and 15% of pediatric malignancies. Soft tissue sarcomas (STS) include more than 50 different subtypes, and the most common subtypes are undifferentiated pleomorphic sarcoma, gastrointestinal stromal tumor, liposarcoma, leiomyosarco-ma, synovial sarcoma, and malignant peripheral nerve sheath tumor. Surgery is still the main therapy method for STS, but it leads to a high recurrence rate, poor prognosis, and unsatisfactory efficacy of chemotherapy. With deeper understanding of the biological behavior of tumors, several emerging targeted drugs have achieved good efficacy. Overall, considering the pathological subtypes, features of the molecular genetics, stage, and prognostic factors of STS patients, the individualized therapy model, including surgery, chemotherapy, ra-diotherapy, and targeted therapy, is recommended for STS patients.